Desmoid tumors: Clinical features and treatment options for advanced disease

Oncologist

Volumn 16, Issue 5, 2011, Pages 682-693

  Kasper, Bernd ^a   Ströbel, Philipp ^a   Hohenberger, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

catenin; Advanced disease; Aggressive fibromatosis; Desmoid tumor; Individualized treatment

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BETA CATENIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; IMATINIB; INDOMETACIN; INDOMETACIN DERIVATIVE; MELPHALAN; METHOTREXATE; NAVELBINE; NILOTINIB; ORAL CONTRACEPTIVE AGENT; SORAFENIB; SULINDAC; TAMOXIFEN; VINBLASTINE; VINCRISTINE;

ABDOMINAL FIBROMATOSIS; ADVANCED CANCER; BETA CATENIN GENE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CTNNB1 GENE; DESMOID TUMOR; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; EVENT FREE SURVIVAL; GASTROINTESTINAL STROMAL TUMOR; GENE; HUMAN; LOW DRUG DOSE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION INJURY; RECURRENCE RISK; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

ADENOMATOUS POLYPOSIS COLI PROTEIN; BETA CATENIN; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; FIBROMATOSIS, ABDOMINAL; FIBROMATOSIS, AGGRESSIVE; HUMANS; MESENTERY; NEOPLASM STAGING;

EID: 79956320765     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0281     Document Type: Review

References (61)

1. Biermann JS. Desmoid tumors. Curr Treat Options Oncol 2000;1:262-266.
2. Micke O, Seegenschmiedt MH; German Cooperative Group on Radiotherapy for Benign Diseases. Radiation therapy for aggressive fibromatosis (desmoid tumors): Results of a national Patterns of Care Study. Int J Radiat Oncol Biol Phys 2005;61:882-891.
3. Bertario L, Russo A, Sala P et al.; Hereditary Colorectal Tumor Registry. Multiple approaches to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003;21:1698-1707.
4. Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg 1996;83:1494-1504.
5. Janinis J, Patriki M, Vini L et al. The pharmacological treatment of aggressive fibromatosis: A systematic review. Ann Oncol 2003;14:181-190.
6. Pignatti G, Barbanti-Bròdano G, Ferrari D et al. Extraabdominal desmoid tumor. A study of 83 cases. Clin Orthop Relat Res 2000;(375):207-213.
7. Knudsen AL, Bülow S. Desmoid tumour in familial adenomatous polyposis. A review of literature. Fam Cancer 2001;1:111-119.
8. Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Soft tissue sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5): v198-v203.
9. Okuno S. The enigma of desmoid tumors. Curr Treat Options Oncol 2006; 7:438-443.
10. Stoeckle E, Coindre JM, Longy M et al. A critical analysis of treatment strategies in desmoid tumours: A review of a series of 106 cases. Eur J Surg Oncol 2009;35:129-134.
11. Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: Analysis of a series and review of the literature. Histopathology 2007;51:509-514.
12. Wu X, Petrovic V, Torode IP et al. Low grade fibromyxoid sarcoma: Problems in the diagnosis and management of a malignant tumour with bland histological appearance. Pathology 2009;41:155-160.
13. Bartuma H, Möller E, Collin A et al. Fusion of the FUS and CREB3L2 genes in a supernumerary ring chromosome in low-grade fibromyxoid sarcoma. Cancer Genet Cytogenet 2010;199:143-146.
14. Wehrli BM, Weiss SW, Yandow S et al. Gardner-associated fibromas (GAF) in young patients: A distinct fibrous lesion that identifies unsuspected Gardner syndrome and risk for fibromatosis. Am J Surg Pathol 2001;25:645-651.
15. Dumont AG, Rink L, Miettinen M et al. Coexistence of gastrointestinal stromal tumor (GIST) with desmoids tumor (DT): Case series of 22 patients [abstract 10052]. J Clin Oncol 2010;28(15 suppl):711s.
16. Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: Comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 2007;31:509-520.
17. Swartz RD. Idiopathic retroperitoneal fibrosis: A review of the pathogenesis and approaches to treatment. Am J Kidney Dis 2009;54:546-553.
18. Lazar AJ, Tuvin D, Hajibashi S et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008;173:1518-1527.
19. Dômont J, Salas S, Lacroix L et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: A potential molecular tool for disease management. Br J Cancer 2010;102:1032-1036.
20. Miyaki M, Konishi M, Kikuchi-Yanoshita R et al. Coexistence of somatic and germ-line mutations of APC gene in desmoid tumors from patients with familial adenomatous polyposis. Cancer Res 1993;53:5079-5082.
21. Vasen HF, van der Luijt RB, Slors JF et al. Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis. Lancet 1996;348:433-435.
22. Wallis YL, Morton DG, McKeown CM et al. Molecular analysis of the APC gene in 205 families: Extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet 1999;36:14-20.
23. Melis M, Zage JS, Sondak VK. Multimodality management of desmoid tumors: How important is a negative surgical margin? J Surg Oncol 2008;98: 594-602.
24. Nakayama T, Tsuboyama T, Toguchida J et al. Natural course of desmoidtype fibromatosis. J Orthop Sci 2008;13:51-55.
25. Lev D, Kotilingam D, Wei C et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007;25:1785-1791.
26. Spear MA, Jennings LC, Mankin HJ et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys 1998;40:637-645.
27. Merchant NB, Lewis JJ, Woodruff JM et al. Extremity and trunk desmoid tumors: A multifactorial analysis of outcome. Cancer 1999;86:2045-2052.
28. Gronchi A, Casali PG, Mariani L et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: A series of patients surgically treated at a single institution. J Clin Oncol 2003;21:1390-1397.
29. Bonvalot S, Eldweny H, Haddad V et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008;34:462-468.
30. Bertagnolli MM, Morgan JA, Fletcher CD et al. Multimodality treatment of mesenteric desmoid tumors. Eur J Cancer 2008;44:2404-2410.
31. Baumert BG, Spahr MO, von Hochstetter A et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network. Radiat Oncol 2007;2:1-12.
32. Jelinek JA, Stelzer KJ, Conrad E et al. The efficacy of radiotherapy as postoperative treatment for desmoid tumors. Int J Radiat Oncol Biol Phys 2001; 50:121-125.
33. Nuyttens JJ, Rust PF, Thomas CR Jr et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. Cancer 2000;88:1517-1523.
34. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys 2008; 71:441-447.
35. Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-beta expression in extraabdominal fibromatosis: An analysis of 40 cases. Cancer 2006;106: 208-213.
36. Hansmann A, Adolph C, Vogel T et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004;100:612-620.
37. Waddell WR, Gerner RE. Indomethacin and ascorbate inhibit desmoid tumours. J Surg Oncol 1980;15:85-90.
38. Signorini S, Frattini M, Negri T et al. Cyclooxygenase-2 and plateletderived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res 2007;13:5034-5040.
39. Skapek SX, Ferguson WS, Granowetter L et al. Vinblastine and methotrexate for desmoid fibromatosis in children: Results of a Pediatric Oncology Group phase II trial. J Clin Oncol 2007;25:501-506.
40. Van der Hul RL, Seynaeve C, van Geel BN et al. Low dose methotrexate and vinblastine, given weekly to patients with desmoid tumours, is associated with major toxicity. Sarcoma 2003;7:153-157.
41. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer 1993;72:3244-3247.
42. Gega M, Yanagi H, Yoshikawa R et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006;24: 102-105.
43. De Camargo VP, Keohan ML, D'Adamo DR et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 2010;116:2258-2265.
44. Constantinidou A, Jones RL, Scurr M et al. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer 2009;45:2930-2934.
45. Lev-Chelouche D, Abu-Abeid S, Nakache R et al. Limb desmoid tumors:A possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Surgery 1999;126:963-967.
46. Grünhagen DJ, de Wilt JH, van Geel AN et al. Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities. Recent Results Cancer Res 2009;179:257-270.
47. Mace J, Sybill Biermann J, Sondak V et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373-2379.
48. Leithner A, Gapp M, Radl R et al. Immunohistochemical analysis of desmoid tumours. J Clin Pathol 2005;58:1152-1156.
49. Heinrich MC, McArthur GA, Demetri GD et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumour). J Clin Oncol 2006;24:1195-1203.
50. Penel N, Le Cesne A, Bui B et al. Imatinib for the treatment of aggressive fibromatosis (desmoid tumors) failing local treatment. Aphase II trial of the French Sarcoma Group. J Clin Oncol 2006;24(18 suppl):Abstract 9516.
51. Penel N, Le Cesne A, Bui BN et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): An FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 2010;22:452-457.
52. Chugh R, Maki RG, Thomas DG et al. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. J Clin Oncol 2006;24(18 suppl):Abstract 9515.
53. ClinicalTrials. gov. Study to Evaluate Imatinib in Desmoid Tumors. Available at http://www.clinicaltrials.gov/ct2/show/NCT01137916?term=NCT01137916& rank=1, accessed June 4, 2010.
54. Gounder M, Lefkowitz R, Hameed M et al. Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF) [abstract 894516]. Presented at the 16th CTOS Annual Meeting, Paris, France, November 11-13, 2010.
55. Kasper B, Dimitrakopoulou-Strauss A, Strauss LG et al. Positron emission tomography in patients with aggressive fibromatosis/desmoid tumors under therapy with imatinib. Eur J Nucl Med Mol Imaging 2010;37:1876-1882.
56. Fiore M, Rimareix F, Mariani L et al. Desmoid-type fibromatosis: A frontline conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009;16:2587-2593.
57. Lazar AJF, Hajibashi S, Lev D. Desmoid tumor: From surgical extirpation to molecular dissection. Curr Opin Oncol 2009;21:352-359.
58. Wehl G, Rossler J, Otten JE et al. Response of progressive fibromatosis to therapy with liposomal doxorubicin. Onkologie 2004;27:552-556.
59. Azzarelli A, Casali P, Fissi S et al. Effective control of advanced aggressive fibromatosis with chemotherapy. Eight years experience with methotrexate and vinblastine in 27 patients. Proceedings of the Fourth Annual Meeting of the Connective Tissue Oncology Society, Milan, Italy, November 4-9, 1997.
60. Weiss AJ, Horowitz S, Lackman RD. Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol 1999;22:193-195.
61. Pilz T, Pilgrim TB, Bisogno G et al. [Chemotherapy in fibromatoses of childhood and adolescence: Results from the Cooperative soft tissue sarcoma study (CWS) and the Italian Cooperative study group (ICG-AIEOP)]. Klin Padiatr 1999;211:291-295. In German.